– USA, CA – Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Suzanne L. Bruhn, Ph.D. to the Company’s Board of Directors, effective immediately. Dr. Bruhn brings more than 20 years of biopharmaceutical experience and a proven track record of success in the development and commercialization of therapies for the treatment of serious diseases with significant unmet needs.
“On behalf of the Board of Directors, I would like to welcome Sue to Retrophin,” said Gary Lyons, Board Chairman. “Sue’s breadth of experience across multiple therapeutic areas and her in-depth knowledge of both corporate and therapeutic development in the rare disease space will be of great value to Retrophin as we enter our next chapter of growth.”
About Dr Sue Bruhn
Since May 2019, Dr. Bruhn has served as the president and CEO of biotechnology company Tiaki Therapeutics Inc., where she is responsible for the vision and overall corporate and capital strategy of the company as it develops innovative therapeutics for patients with neurodegenerative diseases. Prior to her role at Tiaki, Dr. Bruhn served as the president and chief executive officer of Proclara Biosciences where she led the company’s strategy to develop novel treatments for neurodegenerative and peripheral protein misfolding diseases. Before joining Proclara, Dr. Bruhn served as president and chief executive officer of Promedior, Inc., where she focused the company’s strategy on clinical-stage development for rare diseases. Earlier in her career, Dr. Bruhn spent 13 years at Shire Human Genetic Therapies, where she held a series of positions of increasing responsibility, including leading global regulatory affairs, strategic planning and program management.
Dr. Bruhn currently serves as an independent director on the boards of clinical-stage biotechnology companies Aeglea BioTherapeutics and Pliant Therapeutics.
Dr. Bruhn said: “Retrophin exemplifies a deep commitment to delivering treatments to patients and continues to be a leader in the rare disease community. I am excited to join the Board and look forward to contributing to the Company’s continued growth and success.”
She holds a bachelor’s degree in chemistry from Iowa State University, a Ph.D. in chemistry from the Massachusetts Institute of Technology, and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis and IgA nephropathy, rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal, Cholbam, Thiola and Thiola EC.
For more information: http://www.retrophin.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
